| ID | 1162 |
| Name of the vaccine | Hexaxim |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | From 6 weeks |
| Description of the vaccine | DTaP-HepB-IPV-Hib fully liquid hexavalent vaccine. |
| Name of the manufacturer | Sanofi Pasteur |
| Name of the manufacturing country | France |
| Year of manufacture | 2012 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | Vaccine effectiveness was of 96.7% for the full primary series, and 98.5% for booster dose. |
| Vaccine formulation | Whitish, cloudy suspension |
| Dosage | Primary vaccination: Three doses of 0.5 ml and booster dose during the second year. |
| Mechanism of action | Make antibodies and the active substances are fixed onto aluminium compounds. |
| Route of administration | Intramuscular |
| Indications | Primary and booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b. |
| Export | NA |
| Approval | WHO |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis. |
| Side effects of vaccine | Pain and redness at the injection site, irritability and crying. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02428491 |
| Reference | https://www.who.int/immunization_standards/vaccine_quality/pq_284_Hexaxim_1dose_SP_Hexaxim_VPSAR.pdf |
| Other name | NA |
| Additional Links | https://www.ema.europa.eu/en/documents/outside-eu-summary/hexaxim-medicine-overview_en.pdf
|